| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15599112 | IVR | 10 mg/kg | 10 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased cowper's gland weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased weights of penis | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased cowper's gland weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of penis | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased cowper's gland weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 800 mg/kg | 800 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased weights of penis | Reproductive endocrine-mediated perturbations | |
| PMID:21745691 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:28870492 | IVR | 30 mg/L | 30 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations |
| IVR | 30 mg/L | 30 mg/L | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/L | 0.3 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/L | 0.3 mg/L | Affects sertoli cells function | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.